Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
InsuLine Medical Ltd. (TASE: INSL) today announced positive results in the efficacy and safety clinical trial of its insulin patch, InsuPatch for the treatment of Type 1 (juvenile) diabetes. The InsuPatch met its primary endpoint for obtaining US Food and Drug Administration (FDA) approval of the product.
The InsuPatch achieved a relative median increase of 29.7% in insulin levels in the blood within an hour compared with an insulin injection without the product. The FDA requirement was a median increase of at least 10%.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000708732
The InsuPatch achieved a relative median increase of 29.7% in insulin levels in the blood within an hour compared with an insulin injection without the product. The FDA requirement was a median increase of at least 10%.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000708732
